Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session ...Middle East

- ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated - ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen - Study findings warrant further clinical...

Hence then, the article about ionis announces positive data for etesian phase 2b study of antisense medicine targeting pcsk9 at 2022 american college of cardiology scientific session was published today ( Monday 04/04/2022 - 07:35 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session )

Also on site :

• Black Friday in July? Macy’s Drops Dozens of Summertime Deals, From Under-$100 Tech to Trendy Band Tees
• Walmart’s ‘Vibrant’ $40 Floral Area Rug Is Machine-Washable, Pet-Friendly, and Full of Cottagecore Charm
• ‘Avengers: Doomsday’ Trailer Hits 503 Million Views in One Day, Second Biggest Launch in History After ‘Spider-Man: Brand New Day’ (EXCLUSIVE)